http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100584797-B1

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
filingDate 2000-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2006-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2006-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-100584797-B1
titleOfInvention Pharmaceutical Compositions Containing Adenosine Receptor Agonists or Antagonists
abstract Adenosine receptor agonists, particularly agonists that bind to A3 adenosine receptors, induce the production or secretion of G-CSF in the body, prevent or treat toxic side effects of drugs, or prevent leukopenia, especially drug-induced leukopenia. Or to treat and inhibit the growth and proliferation of abnormal cells.n n n Adenosine receptor agonists, adenosine receptor antagonists, G-CSF, leukopenia
priorityDate 1999-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467974431
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425454256
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466238486
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466628232
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20711577

Total number of triples: 36.